

# Treatment of Anti-HLA Donor-Specific Antibodies Results in Increased Infectious Complications and Impairs Survival after Liver Transplantation

Sinem Ünlü <sup>1,2</sup>, Nils Lachmann <sup>2</sup>, Maximilian Jara <sup>1</sup>, Paul Viktor Ritschl <sup>1,3</sup>, Leke Wiering <sup>1</sup>, Dennis Eurich <sup>1</sup>, Christian Denecke <sup>1</sup>, Matthias Biebl <sup>1</sup>, Sascha Chopra <sup>1</sup>, Safak Gül-Klein <sup>1</sup>, Wenzel Schöning <sup>1</sup>, Moritz Schmelzle <sup>1</sup>, Petra Reinke <sup>4</sup>, Frank Tacke <sup>5</sup>, Johann Pratschke <sup>1</sup>, Robert Öllinger <sup>1</sup> and Tomasz Dziudzio <sup>1,\*</sup>

## SUPPLEMENTARY TABLES

**Table S1.** DSA characteristics of 113 DSA-positive patients who underwent LT from deceased donors between 1 January 2008 and 31 December 2015.

	Total ( <i>n</i> = 113)		preformed DSA ( <i>n</i> = 49)		de novo DSA ( <i>n</i> = 55)		<i>p</i> - value <sup>a</sup>	both preformed and de novo DSA ( <i>n</i> = 9)		<i>p</i> - value <sup>b</sup>	<i>p</i> - value <sup>c</sup>
<b>DSA class</b>											
I	47	(41.6)	32	(65.3)	14	(25.5)	<b>&lt;0.001</b>	0	(0.0)	<b>&lt;0.001</b>	0.087
II	35	(31.0)	5	(10.2)	28	(50.9)	<b>&lt;0.001</b>	2	(22.2)	0.309	0.110
I and II	31	(27.4)	12	(24.5)	13	(23.6)	0.919	7	(77.8)	<b>0.002</b>	<b>0.001</b>
<b>DSA count</b>											
I	1	(1–3)	1	(1–3)	1	(1–2)	0.555	4	(3–5)	<b>&lt;0.001</b>	<b>&lt;0.001</b>
II	1	(0–2)	1	(1–2)	1	(0–1)	<b>&lt;0.001</b>	2	(1–3)	0.577	<b>0.029</b>
II	1	(0–1)	0	(0–1)	1	(0–1)	<b>&lt;0.001</b>	2	(1–4)	<b>&lt;0.001</b>	<b>0.003</b>

Annotations: Data presented as *n* (%) or median and Interquartile range (Q1–Q3). <sup>a</sup> Comparison of organ recipients with preformed vs. de novo DSA <sup>b</sup> Comparison with organ recipients with exclusively preformed DSA. <sup>c</sup> Comparison with organ recipients with exclusively de novo DSA. Abbreviations: DSA: Donor-Specific anti-HLA Antibodies, LT: Liver Transplantation.